Viewing Study NCT06284850


Ignite Creation Date: 2025-12-24 @ 4:44 PM
Ignite Modification Date: 2025-12-27 @ 4:49 AM
Study NCT ID: NCT06284850
Status: RECRUITING
Last Update Posted: 2024-02-29
First Post: 2024-01-10
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
Sponsor: Aristotle University Of Thessaloniki
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hematocrit Change View
None Cardiovascular Prevention View
None Empagliflozin View
None SGLT2-Inhibitors View
None Tissue Oxygenation View
Keywords: